SNM Annual Meeting Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     



J Nucl Med. 2008; 49 (Supplement 1):218P
This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Reimold, M.
Right arrow Articles by Bares, R.
PubMed
Right arrow Articles by Reimold, M.
Right arrow Articles by Bares, R.

Neurosciences: Neurology

Neurology Posters

[18F]FDG-PET for diagnosis of dementia in Parkinson's disease

Matthias Reimold1, Inga Liepelt2, Walter Maetzler2, Gerald Reischl1, Daniela Berg2 and Roland Bares1

1 Nuclear Medicine, PET and Radiopharmacy; 2 Hertie-Institute for Clinical Brain Research, University of Tuebingen, Tuebingen, Germany

941

Objectives: Dementia frequently occurs in Parkinson's disease, characterized by cognitive defects, behavioural disturbances and/or visual hallucinations. Objective diagnostic criteria for Parkinson's disease dementia (PDD) are not yet established. In PDD, and to some extent in Parkinson's disease without dementia (PD), cortical hypometabolism was observed with FDG-PET. We evaluated the potential use of FDG-PET for individual diagnosis of PDD.

Methods: 11 PDD patients, 13 PD patients and 7 healthy controls (HC) underwent FDG-PET and extensive neuropsychological testing. FDG-distribution 40min p.i. was spatially normalized (SPM2) and smoothed (12mm). The first 7 PD patients were compared with HC to create a mask comprising all voxels with reduced uptake (P<.05, covariate age). This mask was applied to all subjects to calculate an individual metabolic index (MI: mean FDG uptake within the mask divided by that in remaining gray matter). We compared MI with MMSE (minimental state examination) score, UPDRS III ("on", index for motor symptoms) and an index for frequency and severity of hallucinations (NPIB) using mult. regression (partial corr. r; covariates: age, optionally UPDRS-III).

Results: With the exception of a single patient, there was no overlap between PD (1.086±.011) and PDD (.988±.012). In PD&PDD, MI was correlated with MMSE (r=.71;P<.001) or with NPIB (r=-.51;P=0.008), resp. A similar association between MI and MMSE was found in PD&HC (r=.66;P=.02).

Conclusions: In Parkinsons's disease, alterations in cerebral glucose consumption, represented by a simple index, are closely correlated with cognitive deficits and hallucinations. The presented method appears useful for individual diagnosis of dementia in Parkinson's disease.





This Article
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Reimold, M.
Right arrow Articles by Bares, R.
PubMed
Right arrow Articles by Reimold, M.
Right arrow Articles by Bares, R.